Skip Navigation

European Journal of Heart Failure 2008 10(5):439-445; doi:10.1016/j.ejheart.2008.03.004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lorenz, M.
Right arrow Articles by Stangl, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorenz, M.
Right arrow Articles by Stangl, V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 European Society of Cardiology

Positive inotropic effects of epigallocatechin-3-gallate (EGCG) involve activation of Na+/H+ and Na+/Ca2+ exchangers

Mario Lorenza, Niels Helligeb, Philipp Riedera, Hans-Tilmann Kinkela, Christiane Trimpertc, Alexander Staudtc, Stephan B. Felixc, Gert Baumanna, Karl Stangla and Verena Stangla,*

a Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité — Universitätsmedizin Berlin Campus Mitte, Germany
b Institut für Diagnostische Radiologie, Universitäts-Spital Zürich Zürich, Switzerland
c Klinik für Innere Medizin B, Ernst-Moritz-Arndt-Universität Greifswald Germany

* Corresponding author. Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité — Universitätsmedizin Berlin, CCM, Charitéplatz 1, D-10117 Berlin, Germany. Tel.: +49 30 450 513 153; fax: +49 30 450 513 932. E-mail address: verena.stangl{at}charite.de (V. Stangl).


   Abstract

Background: There is evidence that the tea catechin epigallocatechin-3-gallate (EGCG) modulates myocardial contractility. However, the underlying mechanisms remain to be determined.

Aims: To study potential signalling pathways involved in EGCG-induced contractile parameters.

Methods and results: EGCG increased fractional shortening in rat cardiac myocytes and enhanced intracellular systolic Ca2+ concentrations. In isolated rat hearts, perfusion with EGCG resulted in significant, dose-dependent increase in peak systolic left ventricular pressure, as well as in contraction and relaxation velocities. Heart rate did not change. Inhibition of the β1-receptor with metoprolol had no influence on the contractile effects of EGCG. Furthermore, levels of cAMP and phosphorylation of phospholamban did not change with EGCG, indicating that the beta-receptor pathway is not involved. The L-type Ca2+ channel inhibitors, nifedipine and gallopamil, failed to modulate EGCG-induced increase in contractility. However, the myocardial effects and intracellular calcium transients stimulated by EGCG were significantly reduced by the antagonist of the Na+/H+ exchanger (NHE) methyl-N-isobutyl amiloride (MIA), and by blocking of the reverse mode of the Na+/Ca2+ exchanger (NCX) by KB-R7943.

Conclusion: These results indicate that Ca2+-dependent positive inotropic and lusitropic effects of EGCG are mediated in part via activation of the Na+/H+ exchanger and the reverse mode of the Na+/Ca2+ exchanger in the rat myocardium.

Key Words: EGCG • Myocardium • Contractility • Inotropic • Rat

Received September 4, 2007; Revised January 23, 2008; Accepted March 6, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.